InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

Data ReadoutpositiveifebemtinibGarsorasibPositive

AI Analysis

Summary

InxMed announced publication of clinical results in The Lancet Respiratory Medicine demonstrating promising anticancer activity of ifebemtinib combined with Garsorasib in first-line NSCLC patients with KRAS G12C mutations.

Clinical Trial Data

Outcome Details

Publication in The Lancet Respiratory Medicine featuring promising anticancer activity of ifebemtinib in combination with Garsorasib

Importance:6/10

Sentiment:

0.70

oncologyKRAS G12CNSCLCcombination therapypublicationclinical results

Related Companies

$SHWZ $CHHE $TRAX

Read the original article

Published by PR Newswire Biotech on July 9, 2026 9:28 AM

Read Original